Milena Gilestro

613 total citations
21 papers, 227 citations indexed

About

Milena Gilestro is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Milena Gilestro has authored 21 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 12 papers in Molecular Biology and 8 papers in Genetics. Recurrent topics in Milena Gilestro's work include Multiple Myeloma Research and Treatments (17 papers), Protein Degradation and Inhibitors (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Milena Gilestro is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Protein Degradation and Inhibitors (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Milena Gilestro collaborates with scholars based in Italy, Netherlands and United States. Milena Gilestro's co-authors include Mario Boccadoro, Paola Omedè, Antonio Palumbo, Elona Saraci, Marina Ruggeri, Roberto Passera, Antonella Zucchetto, Valter Gattei, Pellegrino Musto and Monica Astolfi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Milena Gilestro

20 papers receiving 224 citations

Peers

Countries citing papers authored by Milena Gilestro

Since Specialization

Citations

This map shows the geographic impact of Milena Gilestro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milena Gilestro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milena Gilestro more than expected).

Fields of papers citing papers by Milena Gilestro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Milena Gilestro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milena Gilestro. The network helps show where Milena Gilestro may publish in the future.

Co-authorship network of co-authors of Milena Gilestro

This figure shows the co-authorship network connecting the top 25 collaborators of Milena Gilestro. A scholar is included among the top collaborators of Milena Gilestro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milena Gilestro. Milena Gilestro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 2021 ·Annals of Hematology ·Stefania Oliva, Lorenzo De Paoli, Marina Ruggeri, S Caltagirone, Rossella Troia, (unknown), Mattia D’Agostino, Milena Gilestro, Roberto Mina, Elona Saraci, Gloria Margiotta Casaluci, Elisa Genuardi, Sara Bringhen, Mario Boccadoro, Paola Omedè	8
2	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 2020 ·Haematologica ·Roberto Mina, Francesca Bonello, Maria Teresa Petrucci, Anna Marina Liberati, Concetta Conticello, (unknown), Pellegrino Musto, Attilio Olivieri, Giulia Benevolo, Andréa Capra, Milena Gilestro, Piero Galieni, Michèle Cavo, Agostina Siniscalchi, Antonio Palumbo, Vittorio Montefusco, Gianluca Gaïdano, Paola Omedè, Mario Boccadoro, Sara Bringhen	9
3	Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity 2020 ·Blood ·Luca Bertamini, Mariella Grasso, Mattia D’Agostino, Anna Pascarella, Patrizia Tosi, Federico Monaco, Francesco Pisani, Paola Bertazzoni, Milena Gilestro, Andréa Capra, Piero Galieni, Ombretta Annibali, Vincenzo Pavone, S. Molica, Sonia Ronconi, Paola Tacchetti, Pellegrino Musto, Francesca Gay, Mario Boccadoro, Stefania Oliva	12
4	Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM). 2020 ·Journal of Clinical Oncology ·Stefania Oliva, Elisa Genuardi, Angelo Belotti, (unknown), Mónica Galli, Andréa Capra, Massimo Offidani, Federico Vozella, Renato Zambello, Daniel Auclair, Ilan Kirsch, Marina Ruggeri, Allison P. Jacob, A Ledda, Paolo Corradini, Milena Gilestro, Elena Zamagni, Pellegrino Musto, Mario Boccadoro, Francesca Gay	14
5	Long-Term Thymic Function and Reconstitution of the T Cell Compartment after T Cell-Replete Haplo-Identical Allografting 2019 ·Biology of Blood and Marrow Transplantation ·Giuseppe Lia, (unknown), Andrea Evangelista, (unknown), (unknown), (unknown), Lucia Brunello, Milena Gilestro, Marina Ruggeri, (unknown), S Caltagirone, (unknown), Elona Saraci, Moreno Festuccia, Giovannino Ciccone, Enrico Maffini, Mario Boccadoro, Luisa Giaccone, Paola Omedè, Benedetto Bruno	3
6	Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis 2018 ·Cancer ·Manuela Gambella, Paola Omedè, Stefano Spada, (unknown), Milena Gilestro, Elona Saraci, Sara Grammatico, Alessandra Larocca, Concetta Conticello, Annalisa Bernardini, Barbara Gamberi, Rossella Troia, Anna Marina Liberati, Massimo Offidani, Alberto Rocci, Antonio Palumbo, Michèle Cavo, Pieter Sonneveld, Mario Boccadoro, Stefania Oliva	28
7	CD200 included in a 4‐marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 2018 ·Hematological Oncology ·Giovanni D’Arena, Candida Vitale, Giovanni Rossi, Marta Coscia, Paola Omedè, Fiorella D’Auria, Teodora Statuto, (unknown), Stefania Ciolli, Milena Gilestro, Stefano Molica, Silvia Bellesi, (unknown), (unknown), Francesco Autore, Idanna Innocenti, Pellegrino Musto, (unknown), Luca Laurenti, Luigi Del Vecchio	18
8	Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population 2018 ·Clinical Lymphoma Myeloma & Leukemia ·Timothy M. Schmidt, Roberto Mina, Nisha S. Joseph, Francesca Gay, Ajay K. Nooka, Efstathios Kastritis, Stefano Spada, Jonathan L. Kaufman, Vittorio Montefusco, Milena Gilestro, Lawrence Boise, Evangelos Terpos, Sagar Lonial, Mario Boccadoro, Meletios Α. Dimopoulos	1
9	Relevance of sample preparation for flow cytometry 2017 ·International Journal of Laboratory Hematology ·(unknown), Elona Saraci, Milena Gilestro, (unknown), Marina Ruggeri, S Caltagirone, Benedetto Bruno, Mario Boccadoro, Pierluigi Omedè	3
10	A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients 2016 ·Blood ·Sara Bringhen, Valeria Magarotto, Anna Marina Liberati, Angelo Belotti, Alessandra Larocca, Milena Gilestro, Francesca Bonello, Gianluca Gaïdano, Paola Bertazzoni, Raffaella Stocchi, Rossella Ribolla, (unknown), Francesca Patriarca, Roberto Passera, Lorenzo De Paoli, Stefania Oliva, Anna Maria Cafro, Pieter Sonneveld, Antonio Palumbo, Mario Boccadoro	7
11	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity 2016 ·Blood ·Davine Hofste op Bruinink, Stefania Oliva, Lucie Říhová, Bronno van der Holt, Milena Gilestro, Jeroen G. te Marvelde, (unknown), Alexander Schmitz, (unknown), Hans Erik Johnsen, Mario Boccadoro, Roman Hájek, Pieter Sonneveld, Antonio Palumbo, Paola Omedè, Vincent H. J. van der Velden	0
12	Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents 2015 ·Cytometry Part B Clinical Cytometry ·(unknown), Elona Saraci, Milena Gilestro, Valter Gattei, Antonella Zucchetto, Monica Astolfi, Marina Ruggeri, (unknown), Roberto Passera, Antonio Palumbo, Mario Boccadoro, Paola Omedè	43
13	Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma 2015 ·Bone Marrow Transplantation ·Luisa Giaccone, Lucia Brunello, Moreno Festuccia, Milena Gilestro, Enrico Maffini, (unknown), (unknown), Roberto Passera, Mario Boccadoro, Paola Omedè, Benedetto Bruno	5
14	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies 2014 ·Haematologica ·S Caltagirone, Marina Ruggeri, Simona Aschero, Milena Gilestro, (unknown), Francesca Gay, Sara Bringhen, Caterina Musolino, Luca Baldini, Pellegrino Musto, Martina Petrucci, Gianluca Gaïdano, Roberto Passera, Benedetto Bruno, Antonio Palumbo, Mario Boccadoro, Paola Omedè	17
15	In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide 2014 ·Blood ·Manuela Gambella, Paola Omedè, Stefania Oliva, Milena Gilestro, (unknown), Daniela Drandi, Simone Ferrero, Francesca Gay, Francesca Patriarca, (unknown), Maria Teresa Petrucci, Norbert Pescosta, Anna Marina Liberati, Tommaso Caravita, Francesco Di Raimondo, Alberto Rocci, Pellegrino Musto, Mario Boccadoro, Antonio Palumbo	2
16	Immunophenotypic Response After Allografting In Multiple Myeloma 2013 ·Blood ·Luisa Giaccone, Lucia Brunello, Roberto Passera, Moreno Festuccia, Milena Gilestro, Enrico Maffini, (unknown), Mario Boccadoro, Paola Omedè, Benedetto Bruno	2
17	Salvage treatment with pomalidomide-cyclophosphamide prednisone produces similar outcomes as compared to prior therapies in patients with relapsed/refractory multiple myeloma 2013 ·Alessandra Larocca, Vittorio Montefusco, Stefania Oliva, Mauro Spriano, (unknown), Maurizio Genuardi, Delia Rota Scalabrini, Tommasina Guglielmelli, Nicola Giuliani, (unknown), Roberto Mina, Magda Marcatti, Mónica Galli, Milena Gilestro, Claudia Crippa, Isabelle Baldi, D Rossi, Mario Boccadoro, Paolo Corradini, Antonio Palumbo	1
18	Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients 2012 ·Blood ·Antonio Palumbo, Sara Galimberti, Oreste Villani, Agostina Siniscalchi, Eleonora Russo, Giuseppina Uccello, Chiara Cerrato, Milena Gilestro, Davide Rossi, Mario Boccadoro	11
19	Cluster analysis of immunophenotypic data: The example of chronic lymphocytic leukemia 2010 ·Immunology Letters ·Antonella Zucchetto, Ilaria Cattarossi, Paola Nanni, (unknown), Giuseppina Prato, Milena Gilestro, Daniela Marconi, Pietro Bulian, Francesca Maria Rossi, Luigi Del Vecchio	15
20	Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients 2008 ·Blood ·Antonio Palumbo, Patrizia Falco, Francesca Gay, Vittorio Montefusco, Claudia Crippa, Francesca Patriarca, Milena Gilestro, Anna Marina Liberati, Fausto Rossini, Tommaso Caravita, Antonietta Falcone, Federica Cavallo, Paolo Corradini, Giuseppe Rossi, Mario Boccadoro	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact